209 related articles for article (PubMed ID: 38112859)
1. Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.
An Y; Lu W; Li S; Lu X; Zhang Y; Han D; Su D; Jia J; Yuan J; Zhao B; Tu M; Li X; Wang X; Fang N; Ji S
Discov Oncol; 2023 Dec; 14(1):234. PubMed ID: 38112859
[TBL] [Abstract][Full Text] [Related]
2. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
3. Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
Zhang Y; Mou Y; Liang C; Zhu S; Liu S; Shao P; Li J; Wang Z
Prostate; 2021 Feb; 81(3):157-169. PubMed ID: 33338276
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Prognostic Gene Signature in Gastric Cancer Patients.
Xie L; Cai L; Wang F; Zhang L; Wang Q; Guo X
Front Bioeng Biotechnol; 2020; 8():805. PubMed ID: 32850704
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.
Zhang R; Liu F
J Transl Med; 2022 Oct; 20(1):453. PubMed ID: 36195908
[TBL] [Abstract][Full Text] [Related]
9. A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.
Lan Y; Jia Q; Feng M; Zhao P; Zhu M
Front Genet; 2023; 14():1100020. PubMed ID: 37035749
[No Abstract] [Full Text] [Related]
10. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis.
Lai YL; Liu CH; Wang SC; Huang SP; Cho YC; Bao BY; Su CC; Yeh HC; Lee CH; Teng PC; Chuu CP; Chen DN; Li CY; Cheng WC
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326723
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma.
Li R; Shui L; Jia J; Wu C
Front Genet; 2020; 11():906. PubMed ID: 32922438
[TBL] [Abstract][Full Text] [Related]
13. Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes.
Wang S; Li H; Song M; Tao Z; Wu T; He Z; Zhao X; Wu K; Liu XS
PLoS Genet; 2021 May; 17(5):e1009557. PubMed ID: 33945534
[TBL] [Abstract][Full Text] [Related]
14. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
[TBL] [Abstract][Full Text] [Related]
15. Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes.
Yang M; Song B; Liu J; Bing Z; Wang Y; Yu L
PeerJ; 2020; 8():e10297. PubMed ID: 33240632
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts.
Li R; Zhu J; Zhong WD; Jia Z
Cancer Res; 2022 May; 82(9):1832-1843. PubMed ID: 35358302
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy.
Cai Y; Lin J; Wang Z; Ma Y; Pan J; Liu Y; Zhao Z
Front Oncol; 2022; 12():1009921. PubMed ID: 36324578
[TBL] [Abstract][Full Text] [Related]
18. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract][Full Text] [Related]
19. Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer.
Xu L; Pan J; Ding Y; Pan H
Front Genet; 2020; 11():522383. PubMed ID: 33193606
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer.
Liu X; Wang K
Front Genet; 2023; 14():1166668. PubMed ID: 37719710
[No Abstract] [Full Text] [Related]
[Next] [New Search]
